Menin-mll protein-protein interaction inhibitors: a patent review (2021-present)

Introduction Acute leukemia harboring rearrangement of the Mixed lineage leukemia and/or mutation of the nucleophosmin is a type of poorly prognostic and highly malignant leukemia which is extremely difficult to treat. Blocking the protein-protein interaction between Menin and MLL is a strategic approach for treating AL, as a new direction for drug discovery. Many biotech and pharmaceutical companies made great efforts to this drug development field, and a large number of small molecular Menin-MLL PPI inhibitors were reported during the recent three years.